• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatic oncology. >Exploring liver physiology, pathology, TGF-?, EMT, sternness and new developments in liver cancer
【24h】

Exploring liver physiology, pathology, TGF-?, EMT, sternness and new developments in liver cancer

机译：探索肝脏生理学，病理学，TGF-？，EMT，棘手症和肝癌新的发展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Isabel Fabregat speaks to Roshaine Wijayatunga, Managing Commissioning Editor. Isabel Fabregat, PhD, is Senior Investigator, Head of the group "TGF-? and cancer", at the Bellvitge Biomedical Research Institute (IDIBELL) and Associate Professor in the School of Medicine and Health Sciences at the University of Barcelona. She is the President of the Spanish Society for Cell Biology since 2011, she was member of the Executive Board of the Spanish Branch of the European Tissue Culture Society and she is currently member of the Spanish Society for the Study of the Liver, and the International Liver Cancer Association, among others. The current research line of her laboratory focuses on the dissection of the molecular mechanisms induced by TGF-? in liver cells that can explain its different, and sometimes opposite, functions in liver pathologies, in particular fibrosis and hepatocarcinogenesis. Cross-talk between TGF-? and other pathways, in particular EGFR signaling, is also one of the current interests of the lab. From October 2012 she has coordinated an Initial Training Network - Marie Curie European Action that under the acronym of 'IT-LIVER' (Inhibiting TGF-? in Liver Diseases) integrates different European academic groups and small enterprises to develop a multidisciplinary training program for talented young researchers, to prepare them for leading roles in chronic liver disease research. Dr Fabregat has published around 130 articles in indexed journals, as well as several book chapters, with her work published in Hepatology, Journal of Hepatology, Genes & Development, Cancer Research, Oncogene, FASEB Journal, Free Radical in Biology & Medicine, Journal of Cell Science, Journal of Biological Chemistry, among others. She is an editorial member of the World Journal of Gastroenterology, World Journal of Hepatology, Frontiers in Physiology-Gastrointestinal Sciences, Frontiers in Pharmacology, Current Signal Transduction Therapy and Hepatic Oncology.
机译：Isabel Fabregat向Roshaine WijayAtunga发表讲话，管理委托编辑。 Isabel Fabregat，博士，位于Bellvitge生物医学研究所（Idibell）的“TGF-？和癌症”主管高级调查员，并在巴塞罗那大学医学与健康科学学院副教授。她是自2011年以来的西班牙细胞生物学协会主席，她是欧洲组织文化社会的西班牙分支机构执行委员会的成员，而她目前是西班牙语学会肝脏和国际学会的成员。肝癌协会等。当前的研究系列的实验室侧重于TGF-诱导的分子机制的解剖 - ？在肝细胞中，可以解释其不同，有时相反，肝脏病理学的功能，特别是纤维化和肝癌发生。 TGF-之间的跨谈？和其他途径，特别是EGFR信号传导，也是实验室的当前兴趣之一。从2012年10月起，她协调了一个初步培训网络 - 玛丽居里欧洲行动，在“IT-Liver”（抑制TGF-抑制TGF-）（肝脏疾病）的缩写，综合不同的欧洲学术群体和小型企业，为有才能开发多学科培训计划年轻的研究人员，为慢性肝病研究中的主要作用做好准备。法布雷格博士发表于约130篇的索引期刊文章，以及几本书章节，她的作品发表于肝脏，肝脏，基因和发育，癌症研究，癌症，Faseb杂志，生物学和医学中的自由基，杂志细胞科学，生物化学杂志等。她是世界胃肠学杂志，世界肝脏学杂志，生理 - 胃肠道科学的前沿，药理学的前沿，目前信号转导治疗和肝肿瘤学。

著录项

  • 来源
    《Hepatic oncology.》 |2017年第4期|共5页
  • 作者

    Isabel Fabregat;

  • 作者单位

    Bellvitge Biomedical Research Institute (IDIBELL) Gran Via de L'Hospitalet 199.08908 L'Hospitalet;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号